COVALON RECEIVES PATENTS FOR DRUG DELIVERY DEVICE
Covalon Technologies has received patents in France, Germany and the UK for drug delivery via therapeutic hydrogels. These issued patents increase the Canadian company's position in the area of convergent medical devices.
The technology can be used as a drug-delivery platform involving the retention of a drug within liposomes, which are microscopic spheres of lipid designed to act as time-release drug depots.
The medical devices that may benefit from the technology include wound dressings, implantable medical devices and wound-closure systems useful for helping to reduce hospital-acquired infection. The type of therapeutic agent that can be encapsulated within the liposomes is not restricted to a single type of antiseptic or combination of one or more of these. The hydrogel composition might comprise a variety of active agents and include antibiotics, hormones, growth factors and other factors that are beneficial for the medical condition under management.